Pharma News

Phase III trial of Novartis drug Afinitor® met primary endpoint.

Novartis announced today Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex